Counting cells in blood samples may predict cancer treatment's effectiveness

May 14, 2005

ANN ARBOR, Mich. -- Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.

Researchers looked at the number of endothelial cells - normal cells lining the blood vessels - that were circulating in the blood of people with sarcoma. Previous studies have shown that higher levels of circulating endothelial cells are found in people with cancer compared to people who are cancer-free. In this study, researchers found patients whose cancer grew after two months of treatment had high levels of circulating endothelial cells before beginning therapy, while patients whose cancer remained stable had low levels of these cells.

"This test can be used to predict the patient's outcome and survival. In addition, there are a number of drugs available in the clinic, and it may be possible to use this test to monitor the effectiveness of a drug in an individual patient," says Laurence Baker, D.O., professor of internal medicine and pharmacology at the University of Michigan Medical School. Baker will present the study results Saturday, May 14, at the American Society of Clinical Oncology annual meeting in Orlando, Fla.

Circulating endothelial cells are the target of new anti-angiogenesis drugs, which are designed to inhibit the growth of blood vessels that feed tumors. Angiogenesis, the natural process of blood vessel formation, is believed to contribute to the growth and development of cancer cells.

In this multicenter trial, researchers took blood samples from 88 people with advanced sarcoma, a cancer of the soft tissues, and analyzed it to determine the number of endothelial cells circulating in the blood. Angiogenesis inhibitors target these cells, so a change in the number of circulating endothelial cells would suggest a change in tumor status.

"Because the endothelial cell is the target of these anti-angiogenesis drugs, you might be able to very quickly determine if therapy is working," Baker says. Traditionally, patients undergo X-rays and other imaging scans to see if the tumors have disappeared or shrunk.

Study participants were given a new anti-angiogenic drug called ABT-510. As part of a phase II trial, patients with advanced soft tissue sarcoma were randomly assigned to one of two doses of ABT-510. They were assessed every eight weeks to determine whether the tumor was responding to the treatment. The study looked at people with advanced sarcoma that had metastasized, or spread to other parts of the body. Survival rates for this stage of sarcoma are very low: about 10 percent to 15 percent are alive after five years.

In more than one-third of patients taking ABT-510, the cancer had not progressed six months after therapy. With standard drugs, only 14 percent of patients do not see their cancer progress by six months.

ABT-510, an angiogenesis inhibitor in development at Abbott Laboratories, is believed to work by slowing or stopping the growth of blood vessels, thereby choking off a tumor's blood supply. These types of drugs target endothelial cells, causing them to die and preventing new blood vessels from being formed.

In this trial, circulating endothelial cell levels in the study participant's blood were evaluated at the start of the trial, one month in and every two months thereafter. Researchers identified circulating endothelial cells through flow cytometry, an analysis method that separates cells by energy, and by stains that attract to specific types of cells.

Researchers found that patients with low circulating endothelial cell counts, defined as fewer than 15 per sample of blood, remained on the therapy longer than people who had more than 15 circulating endothelial cells per sample at the start of treatment or a month into treatment. Patients were allowed to remain on the therapy until their tumor grew by 50 percent.

The findings suggest doctors may be able to tailor treatment based on the likelihood of response, potentially switching patients from treatments that are not working for them and sparing them months of unnecessary side effects.

ABT-510 is among several angiogenesis inhibitors being tested in different types of cancer, including sarcoma, breast cancer, lung cancer and colon cancer.

In addition to Baker, study authors are George Demetri of the Dana Farber Cancer Institute; David Mendelson and Michael Lobell, both from the University of Arizona; Eric Rowinsky of the Cancer Therapy and Research Center in San Antonio, Texas; and Evelyn McKeegan, Raymond Knight, Dawn Carlson and Paul Cernohous, all from Abbott Laboratories;
Funding for the study came from Abbott Laboratories.

For more information about sarcoma, visit or call the Cancer AnswerLine at 800-865-1125.

Reference: American Society of Clinical Oncology Annual Meeting 2005, abstract No. 9013

University of Michigan Health System

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to